EMA Authorised: Silapo (epoetin zeta) — Stada Arzneimittel AG

View source ↗

Summary

Silapo (epoetin zeta) has been authorised by the EMA for indications related to anemia associated with chronic kidney disease, cancer, and use in autologous blo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Blood Transfusion Autologous
• Cancer
• Kidney Failure Chronic

Drugs mentioned

• Silapo (epoetin zeta)

Snippet

Status: Authorised. Therapeutic area: Anemia;Blood Transfusion, Autologous;Cancer;Kidney Failure, Chronic. MAH: Stada Arzneimittel AG. Decision date: 05/11/2020